基于约束平均剩余寿命的最优治疗方案估计
On Estimating Optimal Regime for Treatment Initiation Time Based on Restricted Mean Residual Lifetime
摘要:
在艾滋病和癌症等许多医学研究中,何时开始对患者进行治疗是一个重要问题。在这篇文章中,我们制定的治疗开始时间问题的时间到事件的数据,并提出了一个最佳的个性化制度,确定最佳的治疗开始时间为个别患者的基础上,他们的特点。不同于现有的最佳治疗方案,其中治疗是在预先指定的时间进行,这里出现了新的挑战,从复杂的缺失机制,在治疗开始时间的数据和连续治疗规则的开始时间。为了解决这些挑战,我们建议使用限制平均剩余寿命作为一个值函数来评估不同的治疗开始制度的性能,并开发一个非参数估计的值函数,这是一致的,即使当治疗开始时间是不完全可观察的,其分布是未知的。我们还建立了在决策规则及其相关的价值函数估计的估计的渐近性质。特别是,估计值函数的渐近分布是非标准的,它遵循加权卡方分布。通过仿真研究评估了所提出的方法的有限样本性能,并进一步说明了乳腺癌数据的应用程序。
英文摘要:
When to initiate treatment on patients is an important problem in many medical studies such as AIDS and cancer. In this article, we formulate the treatment initiation time problem for time-to-event data and propose an optimal individualized regime that determines the best treatment initiation time for individual patients based on their characteristics. Different from existing optimal treatment regimes where treatments are undertaken at a pre-specified time, here new challenges arise from the complicated missing mechanisms in treatment initiation time data and the continuous treatment rule in terms of initiation time. To tackle these challenges, we propose to use restricted mean residual lifetime as a value function to evaluate the performance of different treatment initiation regimes, and develop a nonparametric estimator for the value function, which is consistent even when treatment initiation times are not completely observable and their distribution is unknown. We also establish the asymptotic properties of the resulting estimator in the decision rule and its associated value function estimator. In particular, the asymptotic distribution of the estimated value function is nonstandard, which follows a weighted chi-squared distribution. The finite-sample performance of the proposed method is evaluated by simulation studies and is further illustrated with an application to a breast cancer data.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。